Prevalence of obese US adults could nearly double in percentage under new definition: Study

Researchers from Beth Israel Deaconess, Harvard and Yale applied the Lancet Commission's waist-based obesity criteria to NHANES data (n>14,000, representing 237.7 million U.S. adults, 2017–2023) and found 75.2% of adults met obesity criteria using waist measurements versus 40% when using BMI alone. The study — published in JAMA Network Open — notes nearly all adults aged 50+ would be classified as obese under the new definition, highlights limitations of BMI as a standalone tool, and urges age-specific thresholds and further research before broad adoption, which could affect healthcare policy, resource allocation and market demand for related treatments and services.

Analysis

Market structure: Reclassifying obesity to include waist-based metrics materially expands the addressable population (study implies ~75% vs 40%), which increases potential demand for weight-management drugs, diagnostics and virtual care. Clear near-term winners are large GLP‑1 manufacturers (Novo Nordisk, Eli Lilly) and diagnostic/laboratory players that bill for expanded screening (Hologic, Quest/LabCorp), while payers and lower-margin commercial weight programs (WW) face cost pressure. Pricing power shifts to incumbents with scale in drug manufacturing and specialty pharmacy distribution; smaller therapeutics or boutique programs risk margin compression.

Risk assessment: Tail risks include immediate payer pushback (coverage restrictions or step-therapy) and manufacturing bottlenecks for GLP‑1s; a 30–90 day window is plausible for initial payer guidance, while regulatory adoption could take 6–24 months. Hidden dependencies: increased prevalence on paper does not equal prescription uptake — clinician guidelines, age-specific thresholds and CPT/CMS billing codes are gating factors. Catalysts that would accelerate uptake: CMS coverage expansion, major insurer policy changes, or large pharma capacity increases; contrarily, new adverse-event data or supply caps would reverse momentum.

Trade implications: Over 3–12 months, the highest-conviction trades are long large-cap GLP‑1 makers and diagnostics, financed with defined-risk option structures to hedge policy risk. Relative opportunities include long LLY or NVO versus short WW or smaller tele-nutrition providers; expect elevated options IV around earnings and policy announcements. Entry should be staged: initial exposure ahead of 30–90 day payer signals, scale on confirmed coverage or supply announcements.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Eli Lilly (LLY) over the next 30 days, add up to +2% on any CMS/major-insurer coverage signals within 90 days; set a tactical stop-loss at -12% and a 12–18 month target of +30–50% contingent on uptake.
• Open a 12-month call spread on Novo Nordisk (NVO) (buy 1.5–2% notional 12-month calls, sell a higher strike to finance) to capture upside from expanded addressable market while capping premium exposure; roll/trim if IV spikes >40% before policy announcements.
• Initiate a 1% long position in diagnostic/lab exposure via Hologic (HOLX) or Quest (DGX) (split allocation) to capture increased waist/DEXA/clinical screening volume; increase to 2–3% if CMS assigns new CPT/billing codes within 60–120 days.
• Implement a pair trade: long LLY (1.5%) / short WW International (WW) (1.0%) to express productized drug winners vs commercial diet programs; use equal-dollar sizing, tighten short if WW rallies >25% on headline noise.
• Monitor specific catalysts weekly for 90 days: CMS/Medicare guidance on obesity coverage, major insurer formulary updates, Lancet Commission policy adoption, and quarterly manufacturing capacity announcements from NVO/LLY — treat any positive CMS/insurer policy change as a signal to add 50–100% to GLP‑1 exposure.